Monitor 2026 quarterly filings to verify if the cost-reduction initiatives yield the expected $2–3 million in savings and whether revenue growth accelerates beyond 4.1%.
Price Chart
Executive Summary
Sunshine Biopharma reported fiscal 2025 revenue of $36.3 million, a 4.1% increase from 2024, driven by new product launches and R&D advancements. However, the net loss widened to $5.98 million from $5.13 million due to a $1.75 million non-recurring impairment charge.
Key Financial Metrics
Key Facts
- Fiscal 2025 revenue: $36.3 million (up 4.1% YoY)
- Net loss: $5.98 million (vs. $5.13 million in 2024)
- Gross profit: $12.26 million (vs. $10.67 million in 2024)
- General & administrative expenses rose to $18.48 million from $16.48 million, including a $1.75 million non-recurring impairment charge
- Company launched nine new generic drugs in 2025 and initiated cost-reduction measures expected to save $2–3 million in 2026
Financial Impact
Revenue increased by $1.44 million, but net loss increased by $850,000 due to higher expenses and an impairment charge.
Risk Factors
- Continued net losses despite revenue growth
- Reliance on future cost reductions to improve profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-002781 |
| Document: sunshine_ex9901.htm | 0001683168-26-002781 |
| Document: 0001683168-26-002781-index-headers.html | 0001683168-26-002781 |
| Document: 0001683168-26-002781-index.html | 0001683168-26-002781 |
| Document: 0001683168-26-002781.txt | 0001683168-26-002781 |
| 8-K Data (Synthetic) | 0001683168-26-002781 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 23w ago | 424B4 | $0.0851 $0.0648 | ▲ +23.85% | ▲ +24.84% | — |
Apr 9, 2026 28w ago | 8-K | $0.0851 $0.0851 | · 0.00% | ▼ −8.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers